For people with vitiligo and their caregivers
What this page helps you do
Vitiligo is an autoimmune pigment disorder. Autoimmune means the immune system attacks the body's own cells. Learn about its patterns, pigment-making cells, uncertainty, and common myths.
- Your task
- Understand the current definition, evidence boundary, practical burden, and questions that affect fit.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
What is happening in skin affected by vitiligo?
Vitiligo is a chronic autoimmune disorder in which melanocytes—the cells that make pigment—are attacked and lost or impaired. The visible result is depigmentation: areas that have lost their natural color. Evidence Evidence Evidence
Why this matters
Melanin made by melanocytes contributes color to skin and hair. Current clinical sources describe autoimmunity as central to vitiligo, while recognizing that the biological pathway is more complex than a single cause or event.
Can vitiligo affect more than the skin?
Vitiligo can involve pigment in skin, hair, and mucous membranes. It can also affect wellbeing, and clinicians may consider associated autoimmune conditions as part of a person’s broader medical context. Evidence Evidence Evidence
Why this matters
NIAMS describes depigmented skin, whitening of hair in affected areas, and possible involvement inside the mouth or nose. Clinical guidance also treats psychosocial impact and relevant autoimmune history as meaningful parts of assessment rather than dismissing vitiligo as only cosmetic.
What do “segmental” and “nonsegmental” mean?
They describe clinical patterns, not a severity score. Segmental vitiligo has a characteristic segment-like distribution, while nonsegmental vitiligo is the umbrella category for other recognized patterns; mixed and not-yet-classified presentations also exist. Evidence Evidence
Why this matters
International consensus separates segmental vitiligo from other forms because the distinction can matter for prognosis and management discussions. The same consensus recognizes that a localized patch may remain unclassified until its clinical pattern becomes clearer.
Will vitiligo spread?
One snapshot cannot predict whether an individual’s vitiligo will remain stable, change, or where a new patch might appear. Clinicians assess apparent activity from the history, examination, and change observed across follow-up—not from a promise about the future. Evidence Evidence Evidence
Why this matters
Vitiligo courses vary, and classification guidance distinguishes pattern from disease stability. Recording new areas and changes in existing areas can give a clinician better evidence for describing what has happened so far.
What causes vitiligo?
The best-supported explanation involves autoimmunity interacting with genetic susceptibility and other biological or environmental factors. There is no single behavior, food, stressful event, or personal mistake that explains every case. Evidence Evidence
Why this matters
NIAMS describes vitiligo as autoimmune and notes that researchers continue to study how genes, family history, and possible triggering events contribute. “Associated with” or “noticed after” does not by itself prove that one event caused the condition.
Is vitiligo contagious—and must it be treated?
Vitiligo is not an infection and cannot be caught from another person. Treatment is a choice: some people pursue repigmentation or control of change, some use camouflage or supportive care, and some choose no active treatment. Evidence Evidence Evidence
Why this matters
The autoimmune mechanism means vitiligo is not spread by touch or shared spaces. Dermatology guidance recognizes that goals differ and that a diagnosis should lead to an informed discussion rather than an assumption that every person wants the same outcome.
Questions that can change the next decision
- For your clinicianWhat choices fit the goals I have right now, including no active treatment?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianHow would we revisit the plan if my priorities change?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-03.
- What this evidence supports
- Melanin made by melanocytes contributes color to skin and hair. Current clinical sources describe autoimmunity as central to vitiligo, while recognizing that the biological pathway is more complex than a single cause or event.
- What it does not establish
- This mechanism does not explain why a particular patch appeared in a particular place or why one person’s course differs from another’s. A general mechanism is not an individual forecast.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · independentIndependent source
- Published
- 2022-10-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Pigment Cell & Melanoma Research (Ezzedine K, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2012-05-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports separating segmental vitiligo from nonsegmental forms and recognizing mixed and initially unclassified presentations.
What it does not support
Classification is a clinical and longitudinal judgment; the consensus does not support self-classification from symmetry, one patch or a photograph, and it does not predict an individual response.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- American Academy of DermatologyPatient education · not independentIndependence not established
- Published
- 2026-04-15
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.